Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out ...